• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 14D9/A filed by Turnstone Biologics Corp.

    7/17/25 4:37:10 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TSBX alert in real time by email
    SC 14D9/A 1 d59126dsc14d9a.htm SC 14D9/A SC 14D9/A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14D-9

    Solicitation/Recommendation Statement

    Under Section 14(d)(4) of the Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

    Turnstone Biologics Corp.

    (Name of Subject Company)

     

     

    Turnstone Biologics Corp.

    (Name of Persons Filing Statement)

     

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    90042W100

    (CUSIP Number of Class of Securities)

    Sammy Farah, M.B.A., Ph.D.

    President and Chief Executive Officer

    Turnstone Biologics Corp.

    9310 Athena Circle, Suite 300

    La Jolla, California 92037

    (347) 897-5988

    (Name, address, and telephone number of person authorized to receive notices and communications

    on behalf of the persons filing statement)

    With a copy to:

    Divakar Gupta

    Rama Padmanabhan

    Courtney Tygesson

    Cooley LLP

    55 Hudson Yards

    New York, New York 10001

    (212) 479-6000

     

     

     

    ☐

    Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

     

     
     


    This Amendment No. 1 (this “Amendment”) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (together with any exhibits attached hereto, as it may be amended or supplemented, this “Schedule 14D-9”) previously filed by Turnstone Biologics Corp., a Delaware corporation (“Turnstone” or the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”) on July 11, 2025, relating to the Tender Offer Statement on Schedule TO filed by XOMA Royalty Corporation, a Nevada corporation (“Purchaser”), with the SEC on July 11, 2025 (together with any amendments and supplements thereto, the “Schedule TO”). The Schedule TO relates to the tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (“Turnstone Common Stock,” and shares of Turnstone Common Stock, “Shares”), of Turnstone for (A) $0.34 per Share in cash (the “Cash Amount”), payable subject to any applicable tax withholding and without interest, plus (B) one non-transferable contractual contingent value right per Share which represents the right to receive potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, the Contingent Value Rights Agreement (the “CVR Agreement” and such amount, the “CVR Amount”), subject to any applicable tax withholding and without interest (a “CVR,” and each CVR Amount together with the Cash Amount, the “Offer Price”), all upon the terms and subject to the conditions as set forth in the Offer to Purchase, dated July 11, 2025 (together with any amendments and supplements thereto, the “Offer to Purchase”), and in the related Letter of Transmittal (together with any amendments and supplements thereto, the “Letter of Transmittal,” and together with the Offer to Purchase, the “Offer”).

    Except to the extent specifically provided in this Amendment, the information set forth in the Schedule 14D-9 remains unchanged. Capitalized terms used but not otherwise defined in this Amendment shall have the meanings ascribed to them in the Schedule 14D-9. This Amendment is being filed to reflect certain updates as set forth below.

    ITEM 3. PAST CONTACTS, TRANSACTIONS, NEGOTIATIONS AND AGREEMENTS

    Item 3 of the Schedule 14D-9 is hereby amended and supplemented by replacing the last sentence in the section captioned “—Arrangements Between Turnstone and its Executive Officers, Directors and Affiliates—Employment Arrangements and Change in Control and Severance Benefits Under Existing Relationships—Separation Agreements” on page 8 in its entirety with the following:

    The foregoing summary and description of the material terms of the Separation Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of the Separation Agreements, which are filed as Exhibit (e)(12) and Exhibit (e)(13) hereto and are incorporated herein by reference.

    ITEM 9. EXHIBITS

    Item 9 is hereby amended and supplemented by adding the following exhibits:

     

    Exhibit No.  

    Description

    (e)(12)   Separation and Consulting Agreement, dated July  17, 2025, between Turnstone and Sammy Farah, M.B.A., Ph.D. (incorporated herein by reference to Exhibit 10.2 to Turnstone’s Current Report on Form 8-K/A filed with the SEC on July 17, 2025).
    (e)(13)   Separation and Consulting Agreement, dated July  11, 2025, between Turnstone and Saryah Azmat (incorporated herein by reference to Exhibit 10.3 to Turnstone’s Current Report on Form 8-K/A filed with the SEC on July 17, 2025).


    SIGNATURE

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: July 17, 2025

     

    TURNSTONE BIOLOGICS CORP.
    By:  

    /s/ Sammy Farah

      Sammy Farah
      President and Chief Executive Officer
    Get the next $TSBX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TSBX

    DatePrice TargetRatingAnalyst
    2/5/2025$3.75 → $0.40Overweight → Neutral
    Piper Sandler
    11/15/2024Neutral → Underperform
    BofA Securities
    10/14/2024Buy → Neutral
    BofA Securities
    8/16/2023Market Perform
    SVB Securities
    8/15/2023$20.00Overweight
    Piper Sandler
    8/15/2023$18.00Buy
    BofA Securities
    More analyst ratings

    $TSBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

      EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best

      6/27/25 7:30:00 AM ET
      $TSBX
      $XOMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

      SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. Corporate Updates In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program. As a result, the Company initiated a process to explore a range of potentia

      5/8/25 6:00:49 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer ("SITC") Annual Meeting. Turnstone also presented clinical data at t

      3/28/25 9:03:57 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TSBX
    SEC Filings

    See more

    $TSBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Turnstone Biologics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Turnstone Biologics from Overweight to Neutral and set a new price target of $0.40 from $3.75 previously

      2/5/25 8:04:09 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics downgraded by BofA Securities

      BofA Securities downgraded Turnstone Biologics from Neutral to Underperform

      11/15/24 8:23:44 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics downgraded by BofA Securities

      BofA Securities downgraded Turnstone Biologics from Buy to Neutral

      10/14/24 7:44:47 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 14D9/A filed by Turnstone Biologics Corp.

      SC 14D9/A - Turnstone Biologics Corp. (0001764974) (Subject)

      7/17/25 4:37:10 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 8-K/A filed by Turnstone Biologics Corp.

      8-K/A - Turnstone Biologics Corp. (0001764974) (Filer)

      7/17/25 4:15:41 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 14D9 filed by Turnstone Biologics Corp.

      SC 14D9 - Turnstone Biologics Corp. (0001764974) (Subject)

      7/11/25 7:05:49 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gould Robert J

      4 - Turnstone Biologics Corp. (0001764974) (Issuer)

      7/2/24 4:45:14 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gupta Rishi

      4 - Turnstone Biologics Corp. (0001764974) (Issuer)

      7/2/24 4:45:12 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Rajangam Kanya

      4 - Turnstone Biologics Corp. (0001764974) (Issuer)

      7/2/24 4:45:15 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

      SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

      5/31/24 4:23:52 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

      SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

      4/29/24 8:22:22 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Turnstone Biologics Corp.

      SC 13G - Turnstone Biologics Corp. (0001764974) (Subject)

      3/18/24 9:13:28 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Leadership Updates

    Live Leadership Updates

    See more
    • Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

      SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies," said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. "The next frontier for TIL therapy is to extend its therapeutic activity

      5/13/24 5:01:26 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics Appoints William Waddill to its Board of Directors

      SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

      4/16/24 9:00:00 AM ET
      $ANNX
      $ARWR
      $PTGX
      $TSBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

      Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported

      3/21/24 5:06:41 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Financials

    Live finance-specific insights

    See more
    • Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

      EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best

      6/27/25 7:30:00 AM ET
      $TSBX
      $XOMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer ("SITC") Annual Meeting. Turnstone also presented clinical data at t

      3/28/25 9:03:57 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care